Glucose-lowering effects of incretin-based therapies

R. Keith Campbell, Michael E. Cobble, Timothy S. Reid, Mansur E. Shomali

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Extensive experience from randomized clinical trials demonstrates the efficacy of GLP-1 agonists and DPP-4 inhibitors as monotherapy and in combination with metformin and other agents, although reductions in FPG and PPG, and consequently A1C, are greater with GLP-1 agonists than with DPP-4 inhibitors. This difference may result from the pharmacologic levels of GLP-1 activity that are achieved with the GLP-1 agonists and their direct action on the GLP-1 receptor. The GLP-1 agonists have attributes that would make either of them an appropriate choice in the management of all 3 patients in our case studies, while either DPP-4 inhibitor would be an appropriate choice for Case 1. Differences in dosing, administration, safety, and tolerability should be considered.

Original languageEnglish (US)
Pages (from-to)S10-S19
JournalJournal of Family Practice
Issue number9 SUPPL. 1
StatePublished - Sep 2010
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Glucose-lowering effects of incretin-based therapies'. Together they form a unique fingerprint.

Cite this